Effect of Boswellia in treatment of knee Osteoarthritis

Not Applicable

Recruiting

• Conditions: Knee osteoarthritis.; M17.1; Other prim

• Registration Number: IRCT20150721023282N14
• Lead Sponsor: Fardis pharmaceutical company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

age of 40 - 80 years
Osteoarthritis of at least one knee for at least 3 months based on the diagnostic criteria of American College of Rheumatology (ACR)
Pain score > 4 mm based on the Visual Analogue Scale (VAS)
Grade 2 or 3 of Kellgren-Lawrence scale in knee radiography within the past 3 months

Exclusion Criteria

Use of intra-articular glucocorticoids within the past 3 months
Use of intra-articular sodium hyaluronate within the past 6 months
Use of systemic glucocorticoids (either oral or parenteral) within the past 14 days
Having other osteoarticular disorders (e.g., rheumatoid arthritis and gout)
Skin disorder in knee region
Sensitivity to prescribed topical formulations
Knee arthroscopy within the past 3 months
Illiteracy
Unable to answer the questions
Pregnancy
Lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
WOMAC Index. Timepoint: Before the intervention and 4 weeks after the intervention. Method of measurement: Questionnaire.;Visual analogue scale (VAS). Timepoint: Before the intervention and 4 weeks after the intervention. Method of measurement: scoring on the scale.;Patient global assessment (PGA). Timepoint: Before the intervention and 4 weeks after the intervention. Method of measurement: scoring on the scale.